Drug intelligence / Profile preview

REV-312

Development stage: Unknown
Lead developer: REV Pharmaceuticals
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules

Overview

REV-312 is a proteolysis-targeting chimera (PROTAC) protein degrader currently in Phase 1/2 clinical development for the treatment of immunological and oncological disorders. Developed by the biotechnology company REV, the asset was part of a $1.2 billion acquisition by a larger pharmaceutical manufacturer in February 2026. As a targeted protein degrader, REV-312 utilizes a bifunctional molecule to recruit an E3 ubiquitin ligase to a specific disease-relevant protein, marking it for degradation by the ubiquitin-proteasome system.

Beyond the preview

Go deeper on REV-312.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on REV-312.

Explore the full profile